Trial Profile
Specific Clinical Experience Investigation for Long-term Use of Bydureon Subcutaneous Injection 2 mg and Bydureon Subcutaneous Injection 2 mg PEN
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 08 Apr 2020 Status changed from active, no longer recruiting to completed.
- 19 Apr 2017 Planned End Date changed from 1 Apr 2020 to 30 Apr 2020.
- 19 Apr 2017 Planned primary completion date changed from 1 Apr 2020 to 30 Apr 2020.